Patents by Inventor Garth A. Kinberger

Garth A. Kinberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8987435
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 24, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • Publication number: 20150018540
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate compl in research, diagnostics, and/or therapeutics are described herein.
    Type: Application
    Filed: August 29, 2012
    Publication date: January 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Publication number: 20130035369
    Abstract: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes.
    Type: Application
    Filed: August 3, 2012
    Publication date: February 7, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Eric G. Marcusson, Eric E. Swayze
  • Publication number: 20120115228
    Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell.
    Type: Application
    Filed: January 18, 2012
    Publication date: May 10, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
  • Patent number: 8129515
    Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activity in a cell.
    Type: Grant
    Filed: January 27, 2007
    Date of Patent: March 6, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
  • Publication number: 20110313019
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: October 23, 2009
    Publication date: December 22, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • Publication number: 20110046206
    Abstract: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: June 23, 2008
    Publication date: February 24, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Eric G. Marcusson, Eric E. Swayze
  • Patent number: 7713944
    Abstract: The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: May 11, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Garth A. Kinberger, Martin A. Maier, Richard H. Griffey, Eric E. Swayze
  • Publication number: 20090306178
    Abstract: The present invention provides conjugated double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and/or sugar modified nucleosides. More particularly, the present compositions comprise a linked conjugate group on one strand and a non hybridizing region of 2?-modified nucleosides on the other strand. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: March 27, 2007
    Publication date: December 10, 2009
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Richard H. Griffey, Eric E. Swayze
  • Publication number: 20090221685
    Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activity in a cell.
    Type: Application
    Filed: January 27, 2007
    Publication date: September 3, 2009
    Applicant: ISIS Pharmaceuticals, Inc
    Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
  • Publication number: 20060142232
    Abstract: The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life.
    Type: Application
    Filed: October 13, 2005
    Publication date: June 29, 2006
    Inventors: Garth Kinberger, Martin Maier, Richard Griffey, Eric Swazye